argenx NV ADR
$ 862.18
-2.47%
10 Jun - close price
- Market Cap 55,091,814,000 USD
- Current Price $ 862.18
- High / Low $ 888.50 / 861.26
- Stock P/E 39.11
- Book Value 4.73
- EPS 22.54
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.20 %
- 52 Week High 934.62
- 52 Week Low 510.06
About
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Analyst Target Price
$1026.32
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-02-26 | 2025-10-30 | 2025-07-31 | 2025-05-08 | 2025-03-31 | 2024-10-31 | 2024-07-25 | 2024-05-09 | 2024-02-29 | 2023-10-31 | 2023-07-27 |
| Reported EPS | 4.7 | 6.7945 | 4.44 | 3.26 | 2.27 | 0.7125 | 1.28 | 0.41 | -0.97 | -1.68 | -1.18 | -1.53 |
| Estimated EPS | 4.19 | 5.95 | 3.54 | 2.61 | 2.05 | 1.6979 | 0.06 | -0.99 | -0.81 | -1.7 | -1.34 | -1.65 |
| Surprise | 0.51 | 0.8445 | 0.9 | 0.65 | 0.22 | -0.9854 | 1.22 | 1.4 | -0.16 | 0.02 | 0.16 | 0.12 |
| Surprise Percentage | 12.1718% | 14.1933% | 25.4237% | 24.9042% | 10.7317% | -58.0364% | 2033.3333% | 141.4141% | -19.7531% | 1.1765% | 11.9403% | 7.2727% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 6.27 |
| Currency | EUR |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARGX
2026-06-09 19:39:23
This article analyzes Argenx SE (NL0010832176), an immunology company whose stock performance is closely tied to its lead asset Vyvgart, immunology execution, and U.S. biotech sentiment. The company develops antibody-based medicines for autoimmune diseases, primarily targeting the U.S. and European markets, making it sensitive to clinical data, prescribing trends, and market access in the U.S. Without recent filings or earnings, the article concludes that Argenx remains a "story stock" driven by product momentum, pipeline expectations, and commercial relevance.
2026-06-09 16:39:23
Argenx SE is under investor scrutiny, with focus primarily on the commercial rollout and expansion of its Vyvgart franchise for autoimmune diseases. The company is actively investing in R&D to broaden Vyvgart's indications and strengthen its pipeline, despite operating in a competitive and highly regulated biotech environment. Argenx balances proprietary commercial infrastructure in key markets with strategic partnerships to fund operations and drive long-term growth, making its investment case dependent on future revenue growth and operating leverage.
2026-06-08 11:10:59
Argenx (ARGX) shares jumped 5.8% due to increased investor confidence, fueled by the success of its blockbuster drug Vyvgart, which generated $1.3 billion in Q1 2026 sales and received FDA approval for expanded use. The company is also pursuing further label expansion opportunities and is projected to post significant quarterly earnings and revenue growth. Analyst consensus EPS estimates have been revised upwards, suggesting potential for continued stock appreciation.
2026-06-08 10:50:59
Argenx SE's stock has seen recent volatility due to investors weighing the growth of its autoimmune drug Vyvgart against evolving biotech sentiment and market competition. The company, a major Dutch biopharmaceutical player by revenue, focuses on developing antibody-based therapies for severe autoimmune diseases, with Vyvgart being its primary revenue driver. US investors can access Argenx through its Nasdaq listing, with the company's future performance tied to Vyvgart sales, clinical study outcomes, regulatory decisions, and broader biotech market sentiment.
2026-06-05 11:09:28
argenx SE has appointed Karen Massey as its new Chief Executive Officer, with co-founder Tim Van Hauwermeiren transitioning to Chairperson of the Board of Directors. Massey's appointment was confirmed at the company's Annual General Meeting, where other board reappointments were also approved. The company, which develops antibody-based medicines, also reported strong financial performance and shareholder approvals for its 2025 remuneration report and profit allocation.
2026-06-05 10:39:40
This article discusses the conflicting analyst sentiments regarding Argenx Se (ARGX) and Nanobiotix (NBTX), both in the healthcare sector. William Blair reiterated a "Buy" rating for Argenx Se with a strong consensus price target, while UBS maintained a "Hold" rating for Nanobiotix despite a "Strong Buy" consensus from other analysts with a slight downside from current levels. The piece highlights individual analyst ratings and overall market consensus for both companies.
